Breakthroughs - Breathing Matters

Our research team are constantly searching for those ‘eureka’ moments. We have pleasure in sharing our recent developments with you.

PET scans offer hope for SSc-ILD patients

New research shows PET scans could help predict lung disease progression and guide personalised care

Post-COVID lung microbes stay healthy

New research shows post-COVID lung bacteria look healthy - not like IPF

Shedding light on IPF: neutrophils’ hidden role

Groundbreaking study sheds light on how neutrophils may drive lung scarring

Finding breath through song: a year in review

Find out what patients thought of their Singing for Lungs experience

Do mucus-thinners help people with bronchiectasis?

Recent study shows these treatments are safe but may not reduce flare-ups. Read more about it here.

Guidelines challenged by new bronchiectasis study

Research shows patients with severe symptoms also benefit from azithromycin

Association between bronchiectasis and COPD

Published data from the European Bronchiectasis Registry (EMBARC)

PET/CT Study Reveals Blood Vessel Growth Correlation in Fibrotic Lung Disease

Explore our latest study revealing links between angiogenesis and fibrotic lung disease

Post-TB lung health: Lasting impact beyond treatment

Investigating the lingering lung impact of successfully treated tuberculosis

Cystic Fibrosis drug helps patients with COVID-19

Could a licenced drug that we already use be repurposed?

A step towards a pneumonia vaccine?

Ground breaking research gives us answers

Empowering ILD patients with home monitoring

Study exploring digital device support in managing ILD

ERJ Publication: Mortality markers in CPFE

Lung function findings help insight in combined pulmonary fibrosis and emphysema death rates

Multi-organ MRI findings after COVID-19 admission

Published Article in The Lancet from the PHOSP-COVID research group

Bronchiectasis in Europe

Results from the EMBARC study

One Step Further Towards IPF Personalised Medicine

A simple blood test could be the answer

Could Inhaled Therapies be the Future for Fibrosing Lung Conditions?

New publication on inhaled drug therapy in ILD by the Porter Team

ATTRACT-ive results

The investigational product in the ATTRACT study is C21. C21 is a first-in-class, orally available, low molecular weight, angiotensin II type 2 receptor (AT2R) agonist that activates the “protective arm” of […]

How COVID-19 Is Helping Research Into Pulmonary Fibrosis?

Can COVID-19 give you pulmonary fibrosis?

Are NETS the link between COVID-19 and ILD?

Can Neutrophil Extracellular Traps have the answer?

See how your donations have contributed to our ground-breaking research

2025 ILD Research Report

Sign up!

Receive our latest research updates and news

Sign up to receive our news and updates

Where there's research there's hope

Research into respiratory conditions accounts for just 2% of all the medical research funding in the UK.

Will you support our research?

Yes, I'll donate